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Abstract
Background: Higher plasma D-dimer levels are strong predictors of mortality in HIV+ individuals. The factors associated with
D-dimer levels during HIV infection, however, remain poorly understood.
Methods: In this cross-sectional study, participants in three randomized controlled trials with measured D-dimer levels were
included (N = 9,848). Factors associated with D-dimer were identified by linear regression. Covariates investigated were: age,
gender, race, body mass index, nadir and baseline CD4+ count, plasma HIV RNA levels, markers of inflammation (C-reactive
protein [CRP], interleukin-6 [IL-6]), antiretroviral therapy (ART) use, ART regimens, co-morbidities (hepatitis B/C, diabetes
mellitus, prior cardiovascular disease), smoking, renal function (estimated glomerular filtration rate [eGFR] and cystatin C)
and cholesterol.
Results: Women from all age groups had higher D-dimer levels than men, though a steeper increase of D-dimer with age
occurred in men. Hepatitis B/C co-infection was the only co-morbidity associated with higher D-dimer levels. In this
subgroup, the degree of hepatic fibrosis, as demonstrated by higher hyaluronic acid levels, but not viral load of hepatitis
viruses, was positively correlated with D-dimer. Other factors independently associated with higher D-dimer levels were
black race, higher plasma HIV RNA levels, being off ART at baseline, and increased levels of CRP, IL-6 and cystatin C. In
contrast, higher baseline CD4+ counts and higher high-density lipoprotein cholesterol were negatively correlated with D-
dimer levels.
Conclusions: D-dimer levels increase with age in HIV+ men, but are already elevated in women at an early age due to
reasons other than a higher burden of concomitant diseases. In hepatitis B/C co-infected individuals, hepatic fibrosis, but
not hepatitis viral load, was associated with higher D-dimer levels.
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Introduction
Chronic inflammation and activated coagulation are well-
known features of HIV infection [1,2] and evidence has accrued
indicating that both processes contribute to an increased risk of
death. Out of a panel of inflammatory and coagulation
biomarkers tested in participants of the Strategies for Manage-
ment of Antiretroviral Therapy (SMART) study [3], D-dimer, a
fibrin degradation product, was the most predictive biomarker of
overall mortality [4]. Furthermore, elevated D-dimer levels were
found to be strongly associated with early mortality following
ART initiation among severely immunosuppressed South-African
patients [5].
A strong association between HIV replication and raised D-
dimer levels has been demonstrated. D-dimer levels decline
following antiretroviral therapy (ART) initiation [1,5,6] and
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increase after stopping ART in treatment experienced patients
[1,4]. Correlations of D-dimer with HIV viremia and markers of
endothelial dysfunction and microbial translocation [1,4,7,8] have
also been reported. This favors the hypothesis that HIV replication
and microbial translocation are among the main determinants of
the hypercoagulable state seen in HIV-infected persons.
On the other hand, correlations with other biomarkers may also
indicate that elevations of D-dimer levels are not mainly
determined by HIV infection, but just reflect the presence of co-
morbidities or unmeasured confounders that are truly associated
with activated coagulation. Indeed, an increase of D-dimer levels
with age has been reported in both HIV+ and HIV- individuals
[9,10] and it has been hypothesized that a higher burden of co-
morbidities and an age-related pro-inflammatory state could
explain this [11,12]. Given the complex interaction of multiple
factors leading to inflammation, endothelial dysfunction and
activated coagulation in persons aging with HIV [13], questions
remain as to what is the individual contribution of HIV-specific
factors, demographics, co-infections and co-morbidities to the
variance in D-dimer levels.
The purpose of this study is to identify factors independently
associated with D-dimer levels in a large group of HIV+
individuals. Our main a priori hypotheses were that (1) the higher
levels of D-dimer seen in older individuals are mainly attributable
to a higher burden of co-morbidities and enhanced inflammation,
and (2) that HIV-specific variables (HIV viremia, CD4+ cell count
and ART use) are independently associated with higher D-dimer
levels and that this association remains strong after adjustment for
demographics, co-morbidities, smoking, and biomarkers of
inflammation and renal function.
Materials and Methods
The present study used baseline data from participants in three
randomized controlled trials: (1) SMART (ClinicalTrials.gov
number, NCT00027352) [3]; (2) Evaluation of Subcutaneous
Proleukin in a Randomized International Trial (ESPRIT)
(ClinicalTrials.gov number, NCT00004978); and (3) Subcutane-
ous Recombinant, Human Interleukin-2 in HIV-Infected Patients
with Low CD4+ Counts under Active Antiretroviral Therapy
(SILCAAT) (ClinicalTrials.gov number, NCT00013611) [14],
whose methods have been described in detail elsewhere. Briefly,
the SMART trial compared, in 5,472 individuals with CD4+ .
350 cells/mm3 at baseline, continuous use of ART with structured
treatment interruption guided by CD4+ cell count, involving
stopping ART when CD4+ was .350 cells/mm3 and re-initiating
ART when CD4+ was ,250 cells/mm3. The ESPRIT and
SILCAAT trials compared IL-2 plus ART with ART alone in
4,111 individuals with CD4+ .300 cells/mm3 and 1,695
individuals with CD4+ between 50 and 299 cells/mm3, respec-
tively. Participants from all three trials who had consented to
storing blood for future research and whose serum D-dimer levels
were measured at baseline (N = 9,848) were included in this study.
The SMART, ESPRIT and SILCAAT studies, including the
consent for stored specimens, was approved by the institutional
review board or ethics committee of each clinical site and of the
University of Minnesota. A written informed consent was obtained
from all participants involved in the three trials.
Biomarker Measurements
In SMART participants, D-dimer, CRP, IL-6 and cystatin C
were measured at the Laboratory for Clinical Biochemistry
Research at the University of Vermont (Burlington). D-dimer
levels were measured with immunoturbidometric methods on the
Sta-R analyzer, Liatest D-DI (Diagnostic Stago, Parsippany, New
Jersey, USA). IL-6 was measured with Chemiluminescent
Sandwich ELISA (R&D Systems, Minneapolis, Minnesota,
USA), CRP with a NBTMII nephelometer, N Antiserum to
Human CRP (Siemens Diagnostics, Deerfield, Illinois, USA) and
cystatin C with a BNII nephelometer (Dade Behring Inc.,
Deerfield, Illinois, USA). In the ESPRIT and SILCAAT trials,
laboratory measurements were performed by SAIC-Frederick
(Frederick, Maryland, USA). D-dimer was measured using an
enzyme-linked fluorescent assay (ELISA) on a VIDAS instrument
(bioMerieux Inc., Durham, North Carolina, USA), and CRP and
IL-6 were measured using ELISA (R&D Systems, Minneapolis,
Minnesota, USA). In SMART, lower limits of detection for IL-6,
CRP, D-dimer and cystatin C were 0.16 pg/mL, 0.16 mg/mL,
0.01 mg/mL and 0.195 mg/dL, respectively. In ESPRIT and
SILCAAT, lower limits of detection for IL-6, CRP and D-dimer
were 0.156 pg/mL, 0.078 mg/mL and 0.045 mg/mL. The assays
used to measure D-dimer and CRP, while different, compared
very well on 20 duplicate samples. Estimated glomerular filtration
rate was calculated using the Cockcroft-Gault formula [15] in
ESPRIT and SMART participants. Total cholesterol, low-density
lipoprotein cholesterol (LDLc) and high-density lipoprotein
cholesterol (HDLc) were measured in SMART by Quest
Diagnostics, Inc. (Madison, NJ) using standard enzymatic meth-
ods. LDLc was directly measured. Samples were not required to
be fasting and were analyzed blinded to treatment arm.
The screening of SMART and ESPRIT participants for co-
infection with hepatitis B (HBV) or hepatitis C (HCV) has been
reported elsewhere [16]. Baseline plasma obtained from individ-
uals with antibody tests positive for HBV and HCV was analyzed
for levels of HCV RNA and HBV DNA using branched DNA
assays (Versant HCV RNA 3.0 and Versant HBV DNA 3.0,
respectively; Bayer Diagnostics), whose lower limits of detection
were 615 and 357 IU/mL, respectively. Participants with a
positive HBV/HCV antibody and/or viral load test were
considered to have hepatitis co-infection. Baseline hyaluronic acid
levels were measured in co-infected patients using an enzyme-
linked binding protein assay (Corgenix, Colorado, USA) with a
lower limit of detection of 10 ng/mL [17].
Statistical Analyses
Factors independently associated with elevated D-dimer levels
were identified by multivariable linear regression models. The
distributions of D-dimer, CRP and IL-6 were right-skewed; thus a
logarithmic transformation was used in the analyses. Log2-
transformed D-dimer levels were modeled as the outcome. PROC
REG was used in SAS (version 9.3; SAS Institute, Cary, NC, USA)
to produce estimates with 95% confidence intervals (CI) to assess
the contribution of covariates. Estimates were then exponentiated
in order to correspond to fold differences in D-dimer levels per
unit or category difference in the covariates included in the linear
regression models. The impact of inter-study, inter-laboratory and
inter-method variability was minimized by entering terms for each
study in all models. The goodness of fit of the models was assessed
using the adjusted R2 coefficient. A two-sided P-value of ,0.05
was used as the threshold of statistical significance.
As data on some variables of interest were not collected in all
three trials, the regression models were fitted to three different
datasets:
(1) The largest dataset combining SMART, ESPRIT and
SILCAAT participants (N = 9,848) included: age, gender,
race, body mass index (BMI), CD4+ cell counts (nadir and
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baseline), markers of inflammation (CRP and IL-6), ART use
and ART regimens;
(2) A smaller dataset consisting of SMART and ESPRIT
participants (N = 6,928) included: co-morbidities (HBV and
HCV, diabetes mellitus, prior cardiovascular disease; defined
as prior myocardial infarction, stroke or coronary artery
disease requiring surgical procedure) and renal function
(eGFR);
(3) The smallest dataset consisting only of SMART participants
(N = 4,488), included: smoking, cholesterol levels (LDLc and
HDLc) and additional information on renal function (cystatin
C).
Given the significantly higher levels of D-dimer seen in women,
we found it helpful to investigate if determinants of D-dimer levels
could differ in analyses stratified by gender. Since the three trials
involved participants with different baseline characteristics, we also
investigated interactions between D-dimer levels, study (SMART,
ESPRIT and SILCAAT), plasma HIV RNA levels, inflammatory
biomarkers (IL-6 and CRP) and demographic covariates found to
be correlated with D-dimer levels (age, race and gender).
Table 1. Baseline Characteristics by Dataset ESPRIT, SILCAAT and SMART Patients.
SMART, ESPRIT &





D-dimer (median, IQR) (mg/mL) 0.24 (0.15–0.38) 0.22 (0.15–0.37) 0.20 (0.13–0.36)
Demographics
Age in Years (median, IQR) 42 (36–49) 42 (36–49) 44 (38–50)
Female Gender (%) 21.8 23.2 25.5
Black Race (%) 19.4 21.3 27.8
BMI (median, IQR) 24.34 (22.12–27.00) 24.45 (22.15–27.30) 24.99 (22.50–28.09)
HIV-specific variables
Baseline CD4+ cell count (median, IQR) (cells/mm3) 490 (368–671) 540 (422–722) 601 (470–799)
Nadir CD4+ cell count (median, IQR) (cells/mm3) 200 (84–316) 229 (121–335) 250 (154–358)
Plasma HIV RNA #500 copies/mL (%) 76.4 76.3 73.3
ART regimen
Off ART (%) 8.3 10.1 15.2
PI-based (%) 37.5 33.7 31.8
NNRTI-based (%) 36.5 38.9 37.8
Other (%) 17.7 17.3 15.2
Biomarkers of Inflammation
IL-6 (median, IQR) (pg/mL) 1.80 (1.20–2.89) 1.81 (1.17–2.90) 1.72 (1.07–2.93)
CRP (median, IQR) (mg/mL) 1.59 (0.70–3.67) 1.61 (0.71–3.76) 1.70 (0.71–4.07)
Co-morbidities
Cardiovascular disease (%)* n/a 2.7 3.6
Diabetes Mellitus (%)* n/a 5.3 6.7
Hepatitis B (%)* n/a 3.7 2.2
Hyaluronic Acid (median, IQR) (ng/mL)*** n/a 23.80 (14.63–43.69) n/a
HBV DNA (median, IQR) (IU/mL)*** n/a 71,704 (2,000–100,000,000) n/a
Hepatitis C (%)* n/a 14.4 13.4
Hyaluronic Acid (median, IQR) (ng/mL)**** n/a 33.17 (18.75–59.82) n/a
HCV RNA (median, IQR) (IU/mL)**** n/a 2,576,804 (583,936–7,610,964) n/a
Smoking** n/a n/a 40.5
Renal Function
eGFR (median, IQR) (mL/min per 1.73 m2)* n/a 111.56 (100.66–121.03) 110.82 (100.25–120.56)
Cystatin C (median, IQR) (mg/dL)** n/a n/a 0.81(0.71–0.92)
Cholesterol Levels
Total Cholesterol (median,IQR) (mg/dL)** n/a n/a 192 (164–222)
LDL-c (median,IQR) (mg/dL)** n/a n/a 112 (90–137)
HDL-c (median,IQR) (mg/dL)** n/a n/a 40 (33–51)
*Not ascertained for patients in SILCAAT.
**Not ascertained for patients in SILCAAT or ESPRIT.
***Data available for n = 245 participants.
****Data available for n = 860 participants.
doi:10.1371/journal.pone.0090978.t001
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In the subset of hepatitis co-infected individuals, we sought to
investigate the contribution of liver fibrosis and replication of
hepatitis viruses to the variance of D-dimer levels. We then
entered hyaluronic acid levels (a validated marker of hepatic
fibrosis, which was measured at baseline in 245 study participants
co-infected with HBV and in 860 co-infected with HCV), as well
as HBV and HCV viral load, into models adjusted for
demographics (age, gender and race) and restricted to HBV-
and HCV- co-infected participants, respectively.
Sensitivity Analyses
Correlates of D-dimer levels were also investigated by using
multivariable logistic regression models. Participants were dichot-
omized into two groups: low and elevated D-dimer levels; the
latter defined as levels greater than 0.377 mg/mL (4th quartile for
the participants in all three trials). Odds ratio (OR) with 95% CI
were calculated to assess the contribution of correlates.
We also carried out two additional sensitivity analyses using
linear regression models: (a) stratified by current ART use (i.e., yes
versus no) and (b) stratified by plasma HIV RNA levels (i.e.,
plasma HIV RNA #500 versus .500 copies/mL). Analysis (a)
was performed in order to investigate the effect of plasma HIV
RNA on D-dimer levels, since plasma HIV RNA was not included
in the primary analyses because of the possibility that the
colinearity between ART use and plasma HIV RNA levels could
affect valid interpretation of our findings. Analysis (b) was
performed to determine whether the suppression of viral
replication would change the predictors of D-dimer levels.
Results
Baseline demographic, clinical and laboratory characteristics
are summarized separately for each of the three datasets included
in the analyses and are presented in Table 1. In analyses
investigating possible interactions between study and demographic
covariates, the following interactions were found to be significant:
study and gender (p = 0.0005), and study and race (p,.0001).
There was, however, no evidence of an interaction between study
and age (p = 0.20). Because the interactions suggested only
moderate differences in effect and the biomarker assays compared
well on duplicates, we found it appropriate to fit models to datasets
pooling the three trials. Moreover, given that our main results are
fairly consistent between datasets which used the two different D-
dimer assays we believe that the associations presented in this
study are not artificially influenced by the use of different assays.
Demographics
The demographic factors found to be positively and indepen-
dently correlated with D-dimer levels were older age, black race
and female sex. The results were robust, with similar fold
differences seen consistently across multiple models using different
datasets and after adjustment for an increasing range of covariates
(Figure 1). BMI, on the other hand, was not found to be associated
with D-dimer levels.
In analyses stratified by gender, older age was found to be
independently associated with higher D-dimer levels; the effect of
increasing age on D-dimer was, however, much stronger in men
than in women (Figure 2). Women in all age groups were found to
have significantly higher D-dimer levels when compared to males
aged 25–34 years (data not shown). The interaction between age
and gender was found to be significant (p,.001), but there was no
evidence of an interaction between age and plasma HIV RNA
(p = 0.40) and between age and biomarkers of inflammation
(p = 0.98 for IL-6 and p = 0.33 for CRP).
The addition of an increasing number of covariates in multiple
regression models consisting of SMART and ESPRIT datasets did
not substantially change the power to predict D-dimer levels
(adjusted R2 values ranged from 0.15 to 0.22).
HIV-specific Variables
Uncontrolled HIV infection, as demonstrated by lower baseline
CD4+ cell counts and higher plasma HIV RNA, was found to be
positively correlated with higher D-dimer levels. This could well
explain why being off ART at baseline was also independently
associated with elevated D-dimer. We also found a positive and
independent correlation between nadir CD4+ cell counts and D-
dimer levels. Among those on ART, protease inhibitor (PI)-based
and non-nucleoside reverse transcriptase inhibitor (NNRTI)-based
regimens were associated with similar D-dimer levels and no
significant differences were noted (Figure 3).
Biomarkers of Inflammation
Both CRP and IL-6 were independently and positively
correlated with D-dimer. Once again, the results were robust
and observed consistently in all linear regression models (Figure 4).
The linear positive relationship between IL-6 and D-dimer levels is
graphically illustrated in Figure 5.
Co-morbidities, Renal Function and Cholesterol Levels
Prior cardiovascular disease (Fold Difference 0.90, 95% CI
[0.79–1.03], p = 0.14), smoking (0.98, [0.93–1.03], p = 0.45) and
diabetes mellitus (0.94, [0.85–1.04], p = 0.23) did not have a
significant association with D-dimer levels in adjusted models. On
the other hand, HBV (1.27, [1.07–1.50], p = 0.0061) and HCV
(1.19, [1.10–1.29], p,.0001) co-infection were independently
associated with raised D-dimer levels. In co-infected participants,
the degree of liver damage, as demonstrated by higher hyaluronic
acid levels (1.05[1.01–1.09] per 1 log2 ng/mL, p = 0.0078, for
HBV and 1.05[1.00–1.09], p = 0.0315, for HCV), but not the viral
load of hepatitis viruses (1.01[1.00–1.02] per 1 log2 IU/mL,
p = 0.17, for HBV and 0.99[0.97–1.00], p = 0.09, for HCV) was
found to be positively correlated with D-dimer levels.
Higher eGFR levels at baseline were found to be significantly
associated with lower D-dimer in the dataset consisting of SMART
and ESPRIT participants (0.99 [0.98–1.00] per 10 mL/min per
1.73 m2, p = 0.023). However, in SMART participants, after
further adjustment for cystatin C, as well as for smoking and
cholesterol levels, the association between higher eGFR count and
lower D-dimer was no longer significant (1.02, [1.00–1.04],
p = 0.06). Higher cystatin C levels were strongly associated with
elevated D-dimer (1.37 [1.24–1.51] per 1 log2 mg/dL, p,.0001).
In contrast, higher total (0.97 [0.96–0.98] per 10 mg/dL, p,
.0001) and HDL cholesterol (0.98 [0.96–1.00] per 10 mg/dL, p,
.0151) were found to be associated with lower D-dimer levels.
Sensitivity Analyses
Logistic regression models yielded results highly consistent with
linear models (data not shown). The factors associated with D-
dimer levels did not differ between study participants off and on
ART and between those with and without virological suppression
(data not shown).
Discussion
A better understanding of predictors of plasma D-dimer levels
became particularly relevant in the light of new evidence
indicating that both HIV+ [4,5] and HIV- individuals [18,19]
with higher D-dimer levels are at a significantly increased risk of
Determinants of D-Dimer during HIV Infection
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Figure 1. Demographics and D-dimer levels. (a) SMART/ESPRIT/SILCAAT; adjusted for demographics, HIV-specific variables and biomarkers of
inflammation. (b) SMART/ESPRIT; as in (a) and also adjusted for co-morbidities (CVD, DM and hepatitis B/C) and eGFR. (c) SMART only; as in (b) and
also adjusted for smoking, cystatin C and cholesterol levels.
doi:10.1371/journal.pone.0090978.g001
Figure 2. D-dimer levels across age groups stratified by gender (a). (a) SMART/ESPRIT/SILCAAT; adjusted for demographics, HIV-specific
variables and biomarkers of inflammation.
doi:10.1371/journal.pone.0090978.g002
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death. To our knowledge, this is the largest study investigating
determinants of D-dimer published thus far. We have found that
while a significant increase in D-dimer with age occurs in HIV+
men, HIV+ women have high D-dimer levels from an early age.
These findings cannot be explained by an increased burden of co-
morbidities or enhanced inflammation, as previously hypothe-
sized. In those co-infected with HBV/HCV, hepatic fibrosis, but
not hepatitis virus load, is independently associated with higher D-
dimer. We also observed that HIV-specific variables, other
demographic factors, biomarkers of inflammation, renal function
and cholesterol levels are independently associated with higher D-
dimer levels.
We found that black race, female sex and older age were
demographic factors independently associated with higher D-
dimer levels. African-American ethnicity was also found to be
associated with higher plasma levels of D-dimer in HIV+
participants in the Veterans Aging Cohort Study (VACS) [10]
and HIV- hypertensive adults [20]. Not surprisingly, the inter-
racial variability in circulating D-dimer levels was shown to be, in
part, genetically determined [21].
Increases in D-dimer levels with age have been previously
reported [9,10,20,22] and deleterious interactions between vascu-
lar damage, co-morbidities, inactivity and activated inflammation
have been postulated as possible mechanisms [11,12]. However,
we did not find, except for hepatitis, significant associations
between co-morbidities and D-dimer levels. Moreover, we found
no significant interaction between age and inflammatory bio-
markers. Taken together, our findings suggest that the increase of
D-dimer with age is primarily attributable to causes other than a
higher burden of concomitant diseases or an age-related pro-
inflammatory state. Since elevated D-dimer was found to be
correlated with arterial disease severity [23], worsening subclinical
atherosclerosis may play an important role.
We found a significant interaction between age and gender and
demonstrated that older age was more strongly associated with
higher D-dimer in men than in women. We hypothesize that the
significantly higher D-dimer levels observed in younger women
may be due to higher estrogen levels and higher immune
activation. Pregnancy, hormone replacement therapy and estro-
gen-containing contraceptive pills increase plasma levels of
procoagulant factors and are well-known risk factors for throm-
boembolism [24,25], which suggests a potential interplay between
estrogen and D-dimer. After estrogen levels fall (among post-
menopausal women), the gender difference is then attenuated as
Figure 3. HIV-specific variables and D-dimer levels. (a) SMART/ESPRIT/SILCAAT (N = 9848; 821 of whom were off ART at baseline); adjusted for
demographics, HIV-specific variables and biomarkers of inflammation. (b) SMART/ESPRIT (N = 6928); as in (a) and also adjusted for co-morbidities
(CVD, DM and hepatitis B/C) and eGFR. (c) SMART (N = 4488); as in (b) and also adjusted for smoking, cystatin C and cholesterol levels.
doi:10.1371/journal.pone.0090978.g003
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Figure 4. Biomarkers of Inflammation and D-dimer levels. (a) SMART/ESPRIT/SILCAAT (N = 9848); adjusted for demographics, HIV-specific
variables and biomarkers of inflammation. (b) SMART/ESPRIT (N = 6928); as in (a) and also adjusted for co-morbidities (CVD, DM and hepatitis B/C) and
eGFR. (c) SMART (N = 4488); as in (b) and also adjusted for smoking, cystatin C and cholesterol levels.
doi:10.1371/journal.pone.0090978.g004
Figure 5. Correlation between D-dimer and IL-6 levels*. * Plotted values refer to log10 transformed levels of units of measurement based on
the molecular masses of D-dimer and IL-6 (nmol/L for D-dimer and fmol/L for IL-6).
doi:10.1371/journal.pone.0090978.g005
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determinants of D-dimer levels for both genders may be more
related to similar clinical and environmental factors. HIV+ women
have also been found to have higher activation of CD8+ T cells
than HIV+ men with comparable HIV plasma levels [26] and this
exacerbated immune activation may have contributed to the
higher D-dimer levels observed primarily in pre-menopausal
women.
Significantly higher D-dimer levels have been seen in HIV-
infected patients with ongoing viral replication and lower CD4+
cell counts [4,6,10]. Individuals receiving ART had significantly
lower D-dimer levels than those off ART at baseline, but no
remarkable differences between PI- and NNRTI-based regimens
were noted. The factors independently associated with elevated D-
dimer levels, however, did not differ considerably between
individuals with suppressed or unsuppressed plasma HIV RNA
levels. The control of HIV viral replication, therefore, did not
substantially affect the main factors driving coagulation, a finding
that suggests the potential benefit of adjunctive anti-thrombotic
therapies during HIV infection, even in those with HIV viral
suppression.
The positive correlation between nadir CD4+ cell counts and D-
dimer levels that we observed was surprising and counter-intuitive.
Nadir CD4+ counts were significantly associated with D-dimer
levels only after adjustment for baseline CD4+ counts, but not in
univariable analysis. The interplay between D-dimer levels, CD4+
cell counts and plasma HIV RNA is complex with dynamic
changes after ART initiation [1,5,6] and this may in part be
explained by lower D-dimer levels in participants who had good
response to ART and presented a large increase from nadir to
baseline CD4+ counts. However, this observation may have been a
chance finding and further investigation is required.
Congruent with previous reports [4,21], D-dimer and biomark-
ers of inflammation were positively correlated. Inflammatory
responses promote fibrin formation and lysis, resulting in elevated
D-dimer levels [27], with IL-6 being shown to directly activate the
coagulation cascade [28]. Furthermore, D-dimer and other fibrin
degradation products have been found to modulate the production
of IL-6 and other inflammatory mediators [29]. This is consistent
with a bi-directional interplay between inflammation and coagu-
lation. We have also confirmed a previously reported negative
correlation between HDLc and D-dimer [30]. Indeed, HDLc has
been shown to down-regulate thrombotic pathways by multiple
mechanisms, including inhibition of endothelial and platelet
activation, promotion of endothelium-dependent vasodilatation
and attenuation of thrombin generation [31].
We demonstrated for the first time that the degree of hepatic
fibrosis, as demonstrated by higher hyaluronic acid levels, but not
the replication of hepatitis viruses, was associated with higher D-
dimer levels in co-infected patients. This is consistent with data
from cirrhotic, HIV-uninfected individuals, in whom D-dimer
levels were found to increase as hepatic impairment progresses
[32]. However, similarly to other fibrosis markers, HA is not liver
specific and may reflect other pathologies. Therefore, information
on other measures of hepatic fibrosis, such as Fibroscan, APRI and
FIB-4, would have been helpful. Of interest, recent data
demonstrated that HIV replication, in part through associated
reductions in levels of hepatocyte-dependent anti-coagulant
factors, leads to a net-procoagulant state [33]. Additional research
is needed to better understand the potential consequences of
hepatic function for coagulation abnormalities, and clinical risk,
among HIV positive patients.
Decreased renal function, as demonstrated by lower eGFR, was
associated with elevated D-dimer in partially adjusted models in
this study. We observed, however, that this association became no
longer significant after adjustment for cystatin C, which, in turn,
was found to be positively correlated with D-dimer levels. This
finding indicates that cystatin C, as a surrogate measure of renal
impairment, is a better predictor of D-dimer levels than eGFR.
Higher D-dimer levels in renal failure may reflect both decreased
D-dimer clearance and increased fibrin turnover [34], as well as an
inherent pro-inflammatory state [35].
A number of caveats need to be noted regarding the present
study. First, its cross-sectional design hampered our ability to infer
causality and to characterize associations over time. Second, as
data on variables of interest were not uniformly collected in the
three trials, adjustment for important co-variates had to be done in
smaller datasets. Conversely, given the large sample size of this
study, some of the statistically significant associations we have
found may not be clinically relevant. Finally, we have not
investigated factors found to be associated with higher D-dimer
levels in the general population, such as blood pressure, alcohol
intake and physical activity [36].
In conclusion, D-dimer levels increase with age in HIV+ men,
but are already high in women at an early age. This seems to be
primarily attributable to causes other than a higher burden of
concomitant diseases or an age-related pro-inflammatory state. In
those with HBV/HCV co-infection, the only co-morbidity found
to be associated with raised D-dimer, hepatic fibrosis, but not
hepatitis virus replication, seems to influence D-dimer levels. The
control of viral replication did not substantially affect the main
factors driving coagulation in HIV+ persons and the role of
adjunctive anti-thrombotic therapies should be investigated in this
population. As only 20% of D-dimer variance could be explained
by the factors we investigated, further studies on genetic, socio-
economic and clinical correlates of D-dimer in HIV+ individuals
are warranted. Prospective studies and randomized trials are also
needed to determine whether pharmacologic interventions to
lower elevated D-dimer levels can reduce morbidity and all-cause
mortality during HIV infection. We believe that our findings can
be instrumental in building the basic knowledge and in selecting
suitable candidates for such studies.
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